Results 61 to 70 of about 31,918 (237)

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines

Pharmacy, 2018
Background: Febrile neutropenia (FN) is an oncologic emergency which should be treated immediately with empiric antibiotics. Different institutions observe different antibiograms and use different FN management guidelines.
Doaa Naeem, Majed A. Alshamrani, Mohammed A. Aseeri, Mansoor A. Khan   +3 more
doaj   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, EarlyView.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer, Caroline Glatzel, Philipp Schrüfer, Ingulf Lawrenz, Gabor Dobos, Ulrike Wehkamp, Svea Hüning, René Stranzenbach, Jan P. Nicolay, Matthias Goebeler, Marion Wobser   +10 more
wiley   +1 more source

203. Opportunities for Antimicrobial Stewardship in Febrile Neutropenia [PDF]

, 2020
Christopher Shoff, Jordan Baskett, Julia A. Messina, Arthur W. Baker, Nicholas Turner, Justin Spivey, Rebekah Wrenn, Rebekah W. Moehring, Steven S Spires   +8 more
openalex   +1 more source

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, EarlyView.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Safety and effectiveness of the combination of 5‐azacitidine and ruxolitinib in VEXAS syndrome: A single‐centre experience

British Journal of Haematology, EarlyView.
Gregorio Maria Bergonzi, Enrico Cozzo, Alessandro Tomelleri, Costanza Piccolo, Gianluca Scorpio, Carmelo Gurnari, Francesca Romano, Marco Matucci‐Cerinic, Lorenzo Dagna, Massimo Bernardi, Luca Vago, Fabio Ciceri, Corrado Campochiaro, Elisa Diral   +13 more
wiley   +1 more source

Host Transcriptomics and Culture‐Independent Testing for the Management of Febrile Neutropenia: Data From an Observational Study Conducted in a Bone Marrow Transplant Unit

European Journal of Haematology, EarlyView.
ABSTRACT Background Managing febrile neutropenia is challenging due to the limited sensitivity of blood culture (BC) and the lack of tools differentiating infectious from non‐infectious fever. T2 magnetic resonance (T2MR) is a culture‐independent system detecting bacteria (T2Bacteria) and yeasts (T2Candida); SeptiCyte RAPID is a host response assay ...
Anna Maria Peri, Andrea S. Henden, Ricky Nelles, Mark D. Chatfield, Patrick N. A. Harris, Glen Kennedy, David L. Paterson   +6 more
wiley   +1 more source

FP06.01 Discrete Choice Experiment to Estimate Physicians’ Preferences in Terms of G-CSF use for Febrile Neutropenia Primary and Secondary Prophylaxis [PDF]

, 2021
C. Chouaïd, Florian Scotté, E. Antoine, H. Simon, Nathalie Texier, P. Laplaige   +5 more
openalex   +1 more source